Efficacy of UFT plus Tamoxifen for Estrogen-Receptor-Positive Breast Cancer and Tamoxifen plus UFT for Estrogen-Receptor-Negative Breast Cancer: Adjuvant Therapy after Administration of Mitomycin

Author： Ogita M.  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.23, Iss.11, 2003-01, pp. : 689-699

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Letrozole plus triptorelin suppresses estrogen to a greater extent than tamoxifen and triptorelin in premenopausal women with early breast cancer

By  

Inpharma, Vol. 1, Iss. 1623, 2008-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Tamoxifen Plus Chemotherapy versus Tamoxifen Alone as Adjuvant Therapies for Node-Positive Postmenopausal Women with Early Breast Cancer: A Stochastic Economic Evaluation

By Karnon J.   Brown J.  

PharmacoEconomics, Vol. 20, Iss. 2, 2002-02 ,pp. : 119-137

Adis International

Access to resources Recommend Favorite

Treatment of Estrogen Receptor-Positive Breast Cancer

By  

Current Medicinal Chemistry, Vol. 20, Iss. 5, 2013-02 ,pp. : 596-604

Bentham Science Publishers

Access to resources Recommend Favorite

Switching to adjuvant exemestane after tamoxifen improves disease-free survival in postmenopausal women with hormone receptor-positive early breast cancer

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 23, Iss. 5, 2007-05 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Buserelin plus tamoxifen superior in metastatic breast cancer

By  

Inpharma, Vol. 1, Iss. 1247, 2000-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite